Naz Farha, Hagspiel Nicholas, Xu Feifan, Thompson Brandon, Moreau G Brett, Young Mary, Herbein Joel, Fox Christopher B, Petri William A, Abhyankar Mayuresh M
bioRxiv. 2024 Nov 26:2024.11.25.625229. doi: 10.1101/2024.11.25.625229.
We report a comprehensive evaluation of the toxin B (TcdB) vaccine adjuvanted with a dual Toll-like receptor ligand liposome adjuvant for infection (CDI). The vaccine completely protected mice from a lethal infection. Compared to alum adjuvanted TcdB, it generated functionally superior systemic antibodies and supported strong memory B cell and gut IgA responses. This pharmaceutically acceptable adjuvant platform holds promise for developing a next-generation CDI vaccine.
我们报告了一种用于艰难梭菌感染（CDI）的、佐以双 Toll 样受体配体脂质体佐剂的毒素 B（TcdB）疫苗的全面评估。该疫苗完全保护小鼠免受致死性感染。与明矾佐剂的 TcdB 相比，它产生了功能更优的全身性抗体，并支持强大的记忆 B 细胞和肠道 IgA 反应。这种药学上可接受的佐剂平台有望用于开发下一代 CDI 疫苗。
